Cell-Free DNA Analysis is Crucial
in Organ Health Monitoring
Quantitative analysis of cell-free DNA is recognized as a powerful diagnostic tool to monitor organ health. This non-invasive technique is based on the quantification of donor-derived, cell-free DNA (dd-cfDNA) circulating in the blood of the transplant recipient. Levels of dd-cfDNA may vary with different dynamics for each type of organ transplanted, but elevated levels of donor-derived DNA after a certain time period generally indicate failure of the transplanted graft.
OrganTRACE® - Sensitive Solution for Monitoring Graft Health
Accurate longitudinal analysis of the proportion of donor and recipient DNA enables early diagnosis of transplant rejection and is essential for timely therapeutic intervention. The OrganTRACE® assays are designed for detection and absolute quantification of dd-cfDNA using the highly sensitive digital PCR (dPCR) technology.
All assays are formulated with a Reference Gene (RNase P) Assay which enables the percentage of dd-cfDNA to be calculated.
JETA Molecular is collaborating with Omixon to commercialize OrganTRACE Technology under the HoloGRAFT brand name. Read more about HoloGRAFT on the Omixon product page.
MEASURE
Sample to Answer < 0.5 Day
No Sequencing Required
Absolute Quantification Using dPCR
REAGENTS
45 dPCR Monitoring Assays
Validated Using Bio-Rad QX200TM
Pre-Arrayed Genotyping Plates
SOFTWARE
Automated Protocols
Integrates qPCR and dPCR Workflows and Data
Longitudinal Sample Tracking
